WBAG:GLPG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Galapagos's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GLPG has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.06%

GLPG

3.2%

AT Biotechs

3.2%

AT Market


1 Year Return

45.9%

GLPG

32.2%

AT Biotechs

-19.4%

AT Market

Return vs Industry: GLPG exceeded the Austrian Biotechs industry which returned 31.6% over the past year.

Return vs Market: GLPG exceeded the Austrian Market which returned -19.3% over the past year.


Shareholder returns

GLPGIndustryMarket
7 Day0.06%3.2%3.2%
30 Day0.4%6.6%-5.1%
90 Day-3.5%22.5%7.3%
1 Year45.9%45.9%33.1%32.2%-18.5%-19.4%
3 Yearn/a36.9%34.1%-12.9%-19.5%
5 Yearn/a57.3%52.6%16.8%2.2%

Price Volatility Vs. Market

How volatile is Galapagos's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Galapagos undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GLPG (€178.05) is trading below our estimate of fair value (€656.29)

Significantly Below Fair Value: GLPG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GLPG is poor value based on its PE Ratio (73.4x) compared to the Biotechs industry average (41.7x).

PE vs Market: GLPG is poor value based on its PE Ratio (73.4x) compared to the Austrian market (11.2x).


Price to Earnings Growth Ratio

PEG Ratio: GLPG is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: GLPG is good value based on its PB Ratio (4.1x) compared to the XE Biotechs industry average (4.5x).


Next Steps

Future Growth

How is Galapagos forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

65.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLPG's forecast earnings growth (65.9% per year) is above the savings rate (0.5%).

Earnings vs Market: GLPG's earnings (65.9% per year) are forecast to grow faster than the Austrian market (21.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GLPG's revenue (18.1% per year) is forecast to grow faster than the Austrian market (3.3% per year).

High Growth Revenue: GLPG's revenue (18.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GLPG's Return on Equity is forecast to be low in 3 years time (6.6%).


Next Steps

Past Performance

How has Galapagos performed over the past 5 years?

38.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GLPG has a large one-off loss of €193.9M impacting its March 31 2020 financial results.

Growing Profit Margin: GLPG became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: GLPG has become profitable over the past 5 years, growing earnings by 38.7% per year.

Accelerating Growth: GLPG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GLPG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: GLPG's Return on Equity (5.2%) is considered low.


Next Steps

Financial Health

How is Galapagos's financial position?


Financial Position Analysis

Short Term Liabilities: GLPG's short term assets (€5.8B) exceed its short term liabilities (€622.6M).

Long Term Liabilities: GLPG's short term assets (€5.8B) exceed its long term liabilities (€2.5B).


Debt to Equity History and Analysis

Debt Level: GLPG is debt free.

Reducing Debt: GLPG has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.

Debt Coverage: GLPG has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GLPG has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Galapagos's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GLPG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GLPG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GLPG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GLPG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GLPG's dividend in 3 years as they are not forecast to pay a notable one for the Austrian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Onno van de Stolpe (61yo)

21.5yrs

Tenure

€4,413,471

Compensation

Mr. Onno van de Stolpe co-founded Galapagos NV in 1999 and has been Chief Executive Officer and Managing Director since 1999. Mr. van de Stolpe served as the Managing Director Genomics at IntroGene BV. He  ...


CEO Compensation Analysis

Compensation vs Market: Onno's total compensation ($USD4.99M) is about average for companies of similar size in the Austrian market ($USD4.02M).

Compensation vs Earnings: Onno's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Onno van de Stolpe
Co-Founder21.5yrs€4.41m0.73% 86.3m
Bart Filius
CFO & COO5.58yrs€3.63m0.015% 1.8m
Piet Wigerinck
Chief Scientific Officer8.5yrs€2.50m0.066% 7.8m
Andre Hoekema
Chief Business Officer2.83yrs€3.44m0.034% 4.0m
Walid Abi-Saab
Chief Medical Officer3.33yrs€2.16mno data
Elizabeth Goodwin
Vice President of Investor Relationsno datano datano data
Carmen Vroonen
Senior Director of Communications & Public Affairsno datano datano data
John Montana
Managing Director of Argenta6.92yrsno datano data
Chantal Tasset
Head of Developmentno datano datano data
Ellen Aar
Head of Developmentno datano datano data

6.3yrs

Average Tenure

56yo

Average Age

Experienced Management: GLPG's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Onno van de Stolpe
Co-Founder21.5yrs€4.41m0.73% 86.3m
Rajesh Parekh
Member of Supervisory Board0.25yr€90.00kno data
Katrine Bosley
Member of Supervisory Board0.25yr€45.00kno data
Mary Kerr
Member of Supervisory Board0.25yr€45.00kno data
Howard Rowe
Member of Supervisory Board0.25yr€55.00kno data
Linda Higgins
Member of Supervisory Board0.25yrno datano data
Daniel P. O'Day
Non-Independent Director0.75yrno datano data
Peter Guenter
Member of Supervisory Board0.25yr€30.00kno data
Elisabeth Svanberg
Member of Supervisory Board0.25yrno datano data

0.3yrs

Average Tenure

58yo

Average Age

Experienced Board: GLPG's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.


Top Shareholders

Company Information

Galapagos NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Galapagos NV
  • Ticker: GLPG
  • Exchange: WBAG
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €11.778b
  • Shares outstanding: 65.25m
  • Website: https://www.glpg.com

Number of Employees


Location

  • Galapagos NV
  • Generaal De Wittelaan L11 A3
  • Mechelen
  • Antwerp
  • 2800
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GLPGENXTAM (Euronext Amsterdam)YesOrdinary SharesNLEURMay 2005
GXEDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2005
0JXZLSE (London Stock Exchange)YesOrdinary SharesGBEURMay 2005
GXEXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 2005
GLPG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2005
GLPGABATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 2005
GLPGWBAG (Wiener Boerse AG)YesOrdinary SharesATEURMay 2005
GXEETLX (Eurotlx)YesOrdinary SharesITEURMay 2005
GLPGNasdaqGS (Nasdaq Global Select)SPON ADRUSUSDMay 2008
GXEADB (Deutsche Boerse AG)SPON ADRDEEURMay 2008

Biography

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company’s clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 21:25
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.